Rigel Pharmaceuticals, Inc.

Greetings and welcome to the Rigel Pharmaceuticals Financial Conference Call for the first quarter of 2023. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce our first speaker, Ray Fury, Rigel's Executive Vice President General Counsel, and Corporate Secretary. Thank you, Mr. Fuhrer. You may begin.

Hello. Welcome to our first quarter of 2023 financial results and business update conference call. The financial press release for the first quarter of 2023 was issued a short while ago and can be viewed along with the slides for this presentation in the news and events section of the Investor Relations site on Rigel.com. As a reminder, during today's call, we may make forward-looking statements regarding our financial outlook and our plans and timing for regulatory and product development. These statements are subject to risks Statements are made only as of today's date, and we undertake no obligation to update these forward-looking statements to reflect subsequent events or circumstances. At this time, I'd like to turn the call over to our President, Chief Executive Officer Raul Rodriguez. Raul?

Thank you, Ray, and thank you, everyone, for joining today. Also with me today are Dave Santos, our Chief Commercial Officer, and Dean Shornow, our Chief Financial Officer. Now, beginning on slide five. We are pleased with our strong start to 2023 based on our first quarter, which was marked by significant progress on our commercial business. This positions as well for continued growth in the remainder of 2023 and beyond. Our first approved product, Tavalisa and ITP, had the highest number of bottle ships to patients and clinics in a quarter since launch and a meaningful quarter over quarter sales growth. Despite the typical Q1s challenges, such as those associated with reimbursement, we were able to drive continued momentum for Tavalise, which we believe is a testament to our commercial team's commitment to patients with ITP. We are also pleased to see the continued expansion of Tavalise in patients worldwide, most recently with the launch of Tavalise in Japan by our partner Kisei. Congratulations to them. In addition to Tamaliz, we are executing on our key launch initiatives for ResLydia in relapse or refractory AML. Our commercial team has been driving awareness with key physicians groups and will continue to do so with a particular focus on AML specialists at key academic institutions. Beyond our commercial focus, we are looking to expand our hematology oncology business further through our own internal development stage programs, as well as in licensing opportunities, similar to our approach with ResLydia. I will provide further updates and recent progress on our strategy in these efforts later on in this presentation. With that, I'll turn the call over to Dave for an overview of the quarter. Dave? Thank you, Raul.